Recent advances on the development of pharmacotherapeutic agents on the basis of human serum albumin

Current Pharmaceutical Design

Volumn 21, Issue 14, 2015, Pages 1866-1888

  Liu, Fang ^a   Mu, Jing ^a   Xing, Bengang ^a  

^a Nanyang Technological University   (Singapore)

Author keywords

Covalent conjugation; Drug delivery; Electrostatic interactions; Human serum albumin; Nanoparticle; Pharmacotherapeutic agents; Self assembly

Indexed keywords

CYSTEINE; HUMAN SERUM ALBUMIN; NANOPARTICLE; SERUM ALBUMIN;

ARTICLE; DNA MODIFICATION; DRUG DEVELOPMENT; HUMAN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; STATIC ELECTRICITY; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; MEDICINAL CHEMISTRY; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; TRENDS;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; SERUM ALBUMIN;

EID: 84930195916     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150302115411     Document Type: Article

References (158)

1. [1] Sui M, Liu W, Shen Y. Nuclear drug delivery for cancer chemotherapy. J Control Release 2011; 155: 227-36.
2. [2] Kievit FM, Zhang M. Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater 2011; 23: H217-47.
3. [3] Peer D, Karp JM, Hong S, FaroKHzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nano 2007; 2: 751-60.
4. [4] Komatsu T. Protein-based nanotubes for biomedical applications. Nanoscale 2012; 4: 1910-18.
5. [5] Shimanovich U, Bernardes GJ, Knowles TP, Cavaco-Paulo A. Protein micro-and nano-capsules for biomedical applications. Chem Soc Rev 2014; 43: 1361-71.
6. [6] Lohcharoenkal W, Wang L, Chen YC, Rojanasakul Y. Protein nanoparticles as drug delivery carriers for cancer therapy. BioMed Res Int 2014; 2014: 180549.
7. [7] Sleep D. Albumin and its application in drug delivery. Expert Opin Drug Deliv 2014; 18: 1-20.
8. [8] Fanali G, di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P. Human serum albumin: from bench to bedside. Mol Aspects Med 2012; 33: 209-90..
9. [9] Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release 2012; 157: 168-82.
10. [10] Ming X, Carver K, Wu L. Albumin-based nanoconjugates for targeted delivery of therapeutic oligonucleotides. Biomaterials 2013; 34: 7939-49.
11. [11] Kratz F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008; 132: 171-83.
12. [12] Elsadek B, Kratz F. Impact of albumin on drug delivery-new applications on the horizon. J Control Release 2012; 157: 4-28.
13. [13] Sugio S, Kashima A, Mochizuki S, Noda M, Kobayashi K. Crystal structure of human serum albumin at 2.5 Å resolution. Protein Eng 1999; 12: 439-46.
14. [14] https: //kclpure.kcl.ac.uk/portal/files/12489435/Studentthesis-Beulah_Banfield_2014.pdf accessed on 9/12/2014.
15. [15] Peters Jr, T. In All About Albumin. Peters, T., Ed.; Academic Press: San Diego 1995; 9-11.
16. [16] Ghuman J, Zunszain PA, Petitpas I, Bhattacharya AA, Otagiri M, Curry S. Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol 2005; 353: 38-52.
17. [17] He XM, Carter DC. Atomic structure and chemistry of human serum albumin. Nature 1992; 358: 209-15.
18. [18] http: //gradworks.umi.com/35/00/3500434.html accessed on 10/12/2014.
19. [19] Lexa KW, Dolghih E, Jacobson MP. A Structure-based model for predicting serum albumin binding. PLoS One 2014; 9: e93323
20. [20] Bos OJ, Labro JF, Fischer MJ, Wilting J, Janssen LH. The molecular mechanism of the neutral-to-base transition of human serum albumin Acid/base titration and proton nuclear magnetic resonance studies on a large peptic and a large tryptic fragment of albumin. J Biol Chem 1989; 264: 953-59.
21. [21] Le Gal JM, Manfait M. Conformational changes of human serum albumin in vivo induced by free fatty acids as studied by Fourier transform infrared spectroscopy. Biochim Biophy Acta 1990; 1041: 257-63.
22. [22] Wilting J, Van der Giesen WF, Janssen LH, Weideman MM, Otagiri M, Perrin JH. The effect of albumin conformation on the binding of warfarin to human serum albumin. The dependence of the binding of warfarin to human serum albumin on the hydrogen, calcium, and chloride ion concentrations as studied by circular dichroism, fluorescence, and equilibrium dialysis. J Biol Chem 1980; 255: 3032-7.
23. [23] Kim J, Bronson C, Hayton WL, Radmacher MD, Roopenian DC, Robinson JM, Anderson CL. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am J Physiol-Gastr L 2006; 290: G352-60.
24. [24] Schnitzer JE, Oh P. Albondin-mediated capillary permeability to albumin. Differential role of receptors in endothelial transcytosis and endocytosis of native and modified albumins. J Biol Chem 1994; 269: 6072-82.
25. [25] Peters Jr T. In All About Albumin. Peters, T., Ed.; Academic Press: San Diego, 1995; 76-132
26. [26] Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol 2010; 624: 25-37.
27. [27] Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target 2007; 15: 457-64.
28. [28] Maeda H, Fang J, Inutsuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 2003; 3: 319-28.
29. [29] Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010; 9: 615-27.
30. [30] Stollenwerk MM, Pashkunova-Martic I, Kremser C, et al. Albumin-based nanoparticles as magnetic resonance contrast agents: I. Concept, first syntheses and characterisation. Histochem Cell Biol 2010; 133: 375-404.
31. [31] Zsila F, Bikadi Z, Malik D, Hari P, Pechan I, Berces A, Hazai E. Evaluation of drug-human serum albumin binding interactions with support vector machine aided online automated docking Bioinformatics 2011; 27: 1806-13.
32. [32] Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-79.
33. [33] Zheng YR, Suntharalingam K, Johnstone TC, et al. Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery. J Am Chem Soc 2014; 136: 8790-8.
34. [34] Webb MI, Wu B, Jang T, Chard RA, et al. Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions. Chem Eur J 2013; 19: 17031-42.
35. [35] Enyedy ÉA, Dömötör O, Bali K, Hetényi A, Tuccinardi T, Keppler BK. Interaction of the anticancer gallium (III) complexes of 8-hydroxyquinoline and maltol with human serum proteins. J Bio Inorg Chem 2014; 1-12.
36. [36] Hummer AA, Heffeter P, Berger W, et al. X-ray absorption near edge structure spectroscopy to resolve the in vivo chemistry of the redox-active indazolium trans-[tetrachlorobis(1H-indazole) ruthenate(III)] (KP1019). J Med Chem 2013; 56: 1182-96.
37. [37] Dias DM, Rodrigues JP, Domingues NS, Bonvin AM, Castro, MM. Unveiling the interaction of vanadium compounds with human serum albumin by using 1H STD NMR and computational docking studies. Eur J Inorg Chem 2013: 4619-27.
38. [38] Lipponer KG, Vogel E, Keppler BK. Synthesis, characterization and solution chemistry of trans-indazoliumtetrachlorobis (indazole) ruthenate(III), a new anticancer ruthenium complex IR, UV, NMR, HPLC investigations and antitumor activity crystal structures of trans-1-methyl-indazoliumtetrachlorobis-(1-methylindazole)ruthenate(III) and its hydrolysis product transmonoaquatrichlorobis-(1-methylindazole)-ruthenate(III). Metal-Based Drugs 1996; 3: 243-60.
39. [39] van der Vorst JR, Schaafsma BE, Verbeek, FP, et al. Near-infrared fluorescence sentinel lymph node mapping of the oral cavity in head and neck cancer patients. Oral Oncol 2013; 49: 15-9.
40. [40] Chen Q, Wang C, Zhan Z, et al. Near-infrared dye bound albumin with separated imaging and therapy wavelength channels for imaging-guided photothermal therapy. Biomaterials 2014; 35: 8206-14.
41. [41] Chen Q, Wang C, Cheng L, He W, Cheng Z, Liu, Z. Protein modified upconversion nanoparticles for imaging-guided combined photothermal and photodynamic therapy. Biomaterials 2014; 35: 2915-23.
42. [42] Luo J, Chen LF, Hu P, Chen ZN. Tetranuclear gadolinium(III) porphyrin complex as a theranostic agent for multimodal imaging and photodynamic therapy. Inorg Chem 2014; 53: 4184-91.
43. [43] Digilio G, Tuccinardi T, Casalini F, et al. Study of the binding interaction between fluorinated matrix metalloproteinase inhibitors and human serum albumin. Eur J Med Chem 2014; 79: 13-23.
44. [44] Yang F, Ma ZY, Zhang, Y, et al. Human serum albumin-based design of a diflunisal prodrug. Eur J Pharm Biopharm 2013; 84: 549-54.
45. [45] Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 2006; 13: 236-49.
46. [46] http: //accessmedicine.mhmedical.com/book.aspx?bookID=374 accessed on 8/12/2014
47. [47] Kratz F, Müller-Driver R, Hofmann I, Drevs J, Unger C. A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J Med Chem 2000; 43: 1253-6.
48. [48] Kratz F. DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials. Expert Opin Inv Drug 2007; 16: 855-66.
49. [49] Graeser R, Esser N, Unger H, Fichtner I, Zhu A, Unger C, Kratz F. INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model. Invest New Drug 2010; 28: 14-9.
50. [50] Kratz F, Warnecke A, Scheuermann K, et al. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J Med Chem 2002; 45: 5523-33.
51. [51] http: //www cytrx com/pipeline accessed on 10/12/2014
52. [52] Pichler V, Mayr J, Heffeter, P, et al. Maleimide-functionalised platinum (IV) complexes as a synthetic platform for targeted drug delivery. Chem Commun 2013; 49: 2249-51.
53. [53] Stoddart CA, Nault G, Galkina SA, et al. Albumin-conjugated C34 peptide HIV-1 fusion inhibitor equipotent to C34 and T-20 in vitro with sustained activity in SCID-HU THY/LIV mice. J Bio Chem 2008; 283: 34045-52.
54. [54] Xie D, Yao C, Wang L, et al. An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life. Antimicrob Agents Ch 2010; 54: 191-6.
55. [55] Hettick JM, Siegel PD. Determination of the toluene diisocyanate binding sites on human serum albumin by tandem mass spectrometry. Anal Biochem 2011; 414: 232-38.
56. [56] Hartung G, Stehle G, Sinn H, et al. Phase I trial of methotrexatealbumin in a weekly intravenous bolus regimen in cancer patients. Clin Cancer Res 1999; 5: 753-9.
57. [57] Hartung G, Stehle G, Sinn H. Phase I-trial of a methotrexatealbumin conjugate (MTX-HSA) in cancer patients. Eur J Cancer 1997; 33: S249-50.
58. [58] Jeong H, Huh M, Lee S J, et al. Photosensitizer conjugated human serum albumin nanoparticles for effective photodynamic therapy. Theranostics 2011; 1: 230-9.
59. [59] Josefsen LB, Boyle RW. Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranostics. Theranostics 2012; 2: 916-66.
60. [60] Wang RM, Komatsu T, Nakagawa A, Tsuchida E. Human serum albumin bearing covalently attached iron(II) porphyrins as O2-coordination sites. Bioconjugate Chem 2004; 16: 23-6.
61. [61] Luong A, Issarapanichkit T, Kong SD, Fong R, Yang, J. pHSensitive, N-ethoxybenzylimidazole (NEBI) bifunctional crosslinkers enable triggered release of therapeutics from drug delivery carriers. Org Biomol Chem 2010; 8: 5105-9.
62. [62] Krantz A, Hanel AM, Strug I, et al. Site-specific labeling of a protein lysine residue by novel kinetic labeling combinatorial libraries. Comput Struct Biotechnol J 2014; 9: e201403001.
63. [63] Chen X, Muthoosamy K, Pfisterer A, Neumann B, Weil T. Siteselective lysine modification of native proteins and peptides via kinetically controlled labeling. Bioconjugate Chem 2012; 23: 500-8.
64. [64] Asano S, Patterson JT, Gaj T, Barbas CF. Site-selective labeling of a lysine residue in Human Serum Albumin. Angew Chem Int Ed 2014; 53: 11783-6.
65. [65] Jinno F, Yoneyama T, Morohashi A, Kondo T, Asahi S. Chemical reactivity of ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl)sulfamoyl] cyclohex-1-ene-1-carboxylate (TAK-242) in vitro. Biopharm Drug Dispos 2011; 32: 408-25.
66. [66] Spicer CD, Davis BG. Selective chemical protein modification. Nat Commun 2014; 5: 4740.
67. [67] Baslé E, Joubert N, Pucheault M. Protein chemical modification on endogenous amino acids. Chem Biol 2010; 17: 213-27.
68. [68] Tanaka T, Kamiya N, Nagamune, T, N-terminal glycine-specific protein conjugation catalyzed by microbial transglutaminase. Febs Lett 2005; 579: 2092-6.
69. [69] Chen T, Embree HD, Wu LQ, Payne GF. In vitro proteinpolysaccharide conjugation: Tyrosinase-catalyzed conjugation of gelatin and chitosan. Biopolymers 2002; 64: 292-302.
70. [70] Heck T, Faccio G, Richter M, Thöny-Meyer L. Enzyme-catalyzed protein crosslinking. Appl Microbiol Biot 2013; 97: 461-475.
71. [71] Rollett A, Thallinger B, Ohradanova-Repic A. Enzymatic synthesis of antibody-human serum albumin conjugate for targeted drug delivery using tyrosinase from Agaricus bisporus. Rsc Adc 2013; 3: 1460-7.
72. [72] Torchilin V. Intracellular delivery of protein and peptide therapeutics. Drug Discov Today: Technologies 2008; 5: e95-103.
73. [73] Chaudhury C, Brooks CL, Carter DC, Robinson JM, Anderson CL. Albumin binding to FcRn: distinct from the FcRn-IgG interaction. Biochemistry 2006; 45: 4983-90.
74. [74] Tuan GCV, Kragh-Hansen U, Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharmaceut Res 2002; 19: 569-77.
75. [75] Kratz F, Elsadek B. Clinical impact of serum proteins on drug delivery. J Control Release 2012; 161: 429-45.
76. [76] Liu M, Huang Y, Hu L, et al. Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion. BMC Biotechnology 2012; 12: 68.
77. [77] Goldbach-Mansky R. Blocking interleukin-1 in rheumatic diseases. Ann Ny Acad Sci 2009; 1182: 111-23.
78. [78] Berger V, Richter F, Zettlitz K, Unverdorben F, Scheurich P, Herrmann A, Pfizenmaier K, Kontermann R E. An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF action Protein. Eng Des Sel 2013; 26: 581-7.
79. [79] Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death & Differentiation 2003; 10: 45-65.
80. [80] Kontermann R E, Münkel S, Neumeyer J, et al. A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action. J Immunother 2008; 31: 225-34.
81. [81] Spooner R, Yilmaz Ö. The Role of Reactive-oxygen-species in microbial persistence and inflammation. Int J Mol Sci 2011; 12: 334-52.
82. [82] Vlahos R, Stambas J, Selemidis S. Suppressing production of reactive oxygen species (ROS) for influenza A virus therapy. Trends Pharmacol Sci 2012; 33: 3-8.
83. [83] Nakamura H, Herzenberg LA, Bai J, et al. Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis. Proc Natl Acad Sci USA 2001; 98: 15143-8.
84. [84] Kodama A, Watanabe H, Tanaka R, et al. A human serum albumin-thioredoxin fusion protein prevents experimental contrastinduced nephropathy. Kidney Int 2013; 83: 446-54.
85. [85] Tanaka R, Ishima Y, Enoki Y, et al. Therapeutic impact of human serum albumin–thioredoxin fusion protein on influenza virusinduced lung injury mice. Front immunol 2014; 5: 561.
86. [86] Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm 2003; 257: 169-80.
87. [87] Gallo JM, Hung CT, Perrier DG. Analysis of albumin microsphere preparation. Int J Pharm, 1984; 22: 63-74.
88. [88] Lin W, Coombes A, Davies M, Davis S, Illum L. Preparation of sub-100 nm human serum albumin nanospheres using a pHcoacervation method. J Drug Target 1993; 1: 237-43.
89. [89] Lee SH, Heng D, Ng WK, Chan HK, Tan RB. Nano spray drying: A novel method for preparing protein nanoparticles for protein therapy. Int J Pharm 2011; 403: 192-200.
90. [90] Ding D, Tang X, Cao X, Wu J, Yuan A, Qiao Q, Pan J, Hu, Y, Novel self-assembly endows human serum albumin nanoparticles with an enhanced antitumor efficacy. AAPS PharmSciTech, 2014; 15: 213-222
91. [91] Xu R, Fisher, M, Juliano RL, Targeted albumin-based nanoparticles for delivery of amphipathic drugs. Bioconjugate Chem 2011; 22: 870-8.
92. [92] Wang W, Huang Y, Zhao S, Shao T. Cheng Y. Human serum albumin (HSA) nanoparticles stabilized with intermolecular disulfide bonds. Chem Commun 2013; 49: 2234-6.
93. [93] Zhao S, Wang W, Huang Y, Fu Y, Cheng Y. Paclitaxel loaded human serum albumin nanoparticles stabilized with intermolecular disulfide bonds. MedChemComm 2014; 5: 1658-63.
94. [94] http: //digital.library.louisville.edu/utils/getfile/collection/ etd/id/2727/filename/5524.pdf accessed on 15/12/2014
95. [95] Bououdina M. Handbook of Research on Nanoscience, Nanotechnology, and Advanced Materials IGI Global. 2014.
96. [96] http: //www cancer gov/cancertopics/druginfo/fda-nanoparticlepaclitaxel accessed on 18/11/2014
97. [97] Cortes J, Saura C. Nanoparticle albumin-bound (nab™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer. EJC Supplements 2010; 8: 1-10.
98. [98] Kouchakzadeh H, Shojaosadati SA, Shokri F. Efficient loading and entrapment of tamoxifen in human serum albumin based nanoparticulate delivery system by a modified desolvation technique Chem Eng Res Des 2014; 92: 1681-92.
99. [99] Avachat A, Oswal Y, Gujar K, Shah R. Preparation and characterization of rivastigmine loaded human serum albumin (HSA) nanoparticles. Curr Drug Deliv 2014; 11: 359-70.
100. [100] Gaca S, Reichert S, Multhoff G, et al. Targeting by cmHsp70 1-antibody coated and survivin miRNA plasmid loaded nanoparticles to radiosensitize glioblastoma cells. J Control Release 2013; 172: 201-6.
101. [101] Yuan A, Wu J, Song C, et al. A novel self-assembly albumin nanocarrier for reducing doxorubicin-mediated cardiotoxicity. J Pharm Sci 2013; 102: 1626-35.
102. [102] Rollett A, Reiter T, Ohradanova-Repic A, et al. HSA nanocapsules functionalized with monoclonal antibodies for targeted drug delivery. Int J Pharm 2013; 458: 1-8.
103. [103] Lee HJ, Park HH, Kim J A, et al. Enzyme delivery using the 30Kc19 protein and human serum albumin nanoparticles. Biomaterials 2014; 35: 1696-704.
104. [104] Bae S, Ma K, Kim TH, et al. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types. Biomaterials 2012; 33: 1536-46.
105. [105] Li H, Qian ZM. Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev 2002; 22: 225-50.
106. [106] Taheri A, Dinarvand R, Atyabi F, Ghahremani MH, Ostad SN, Trastuzumab decorated methotrexate-human serum albumin conjugated nanoparticles for targeted delivery to HER2 positive tumor cells. Eur J Pharm Sci, 2012; 47: 331-40.
107. [107] Wu J, Song C, Jiang, C, Shen X, Qiao Q, Hu Y. Nucleolin targeting AS1411 modified protein nanoparticle for antitumor drugs delivery. Mol Pharm 2013; 10: 3555-63.
108. [108] Wu Y, Ng DY, Kuan SL, Weil T. Protein-polymer therapeutics: a macromolecular perspective. Biomaterials Science 2015; DOI: 10 1039/C4BM00270A.
109. [109] Boyer C, Huang X, Whittaker MR, Bulmus V, Davis TP. An overview of protein-polymer particles. Soft Matter 2011; 7: 599-14.
110. [110] Banerjee SS, Aher N, Patil R, Khandare J. Poly(ethylene glycol)-Prodrug conjugates: concept, design, and applications. J Drug Deliv 2012; 17.
111. [111] Bhattacharya A, Prajapati R, Chatterjee S, Mukherjee TK. Concentration-dependent reversible self-oligomerization of serum albumins through intermolecular
112. [112] Zhao T, Cheng Y, Tan H, et al. Site-specific chemical modification of human serum albumin with polyethylene glycol prolongs halflife and improves intravascular retention in mice. Bio Pharm Bulletin 2012; 35: 280-8.
113. [113] Byeon HJ, Min SY, Kim I, et al. Human serum albumin-TRAIL conjugate for the treatment of rheumatoid arthritis. Bioconjugate Chem 2014; 25: 2212-21.
114. [114] Zhao T, Yang Y, Zong A, et al. N-terminal PEGylation of human serum albumin and investigation of its pharmacokinetics and pulmonary microvascular retention. Bioscience trends 2012; 6: 81-8.
115. [115] Wu Y, Pramanik G, Eisele K, Weil T. Convenient approach to polypeptide copolymers derived from native proteins. Biomacromolecules 2012; 13: 1890-8.
116. [116] Wu Y, Chakrabortty S, Gropeanu, RA, et al. pH-responsive quantum dots via an albumin polymer surface coating. J Am Chem Soc 2010; 132: 5012-4.
117. [117] Kuan SL, Stöckle B, Reichenwallner J, et al. Dendronized albumin core-shell transporters with high drug loading capacity. Biomacromolecules 2013; 14: 367-76.
118. [118] Wu Y, Ihme S, Feuring-Buske M, et al. A core-shell albumin copolymer nanotransporter for high capacity loading and two-step release of doxorubicin with enhanced anti-leukemia activity. Adv Healthc Mater 2013; 2: 884-94.
119. [119] Ruso JM, Attwood D, García M, et al. Interaction of amphiphilic propranolol hydrochloride with haemoglobin and albumin in aqueous solution. Langmuir 2000; 16: 10449-55.
120. [120] Verma A, Stellacci F. Effect of surface properties on nanoparticlecell interactions. Small 2010; 6: 12-21.
121. [121] Zhang S, Doschak MR., Uluda H. Pharmacokinetics and bone formation by BMP-2 entrapped in polyethylenimine-coated albumin nanoparticles. Biomaterials 2009; 30: 5143-55.
122. [122] Abbasi S, Paul A, Prakash S. Investigation of siRNA-loaded polyethylenimine-coated human serum albumin nanoparticle complexes for the treatment of breast cancer. Cell Biochem Biophys 2011; 61: 277-87.
123. [123] Abbasi S, Paul A, Shao W, Prakash S. Cationic albumin nanoparticles for enhanced drug delivery to treat breast cancer: preparation and in vitro assessment. J Drug Deliv 2012; 2012: 686108.
124. [124] Zhu Q, Jia L, Gao Z, Wang C, Zhang J, Dong L. A tumor environment responsive doxorubicin-loaded nanoparticle for targeted cancer therapy. Mol Pharm 2014; 11: 3269-78.
125. [125] Kadlecova Z, Rajendra Y, Matasci M, et al. DNA delivery with hyperbranched polylysine: A comparative study with linear and dendritic polylysine. J Control Release 2013; 169: 276-88.
126. [126] Stiriba SE, Frey H, Haag R. Dendritic polymers in biomedical applications: from potential to clinical use in diagnostics and therapy. Angew Chem Int Ed 2002; 41: 1329-34.
127. [127] Giri J, Diallo MS, Simpson AJ. Interactions of poly(amidoamine) dendrimers with human serum albumin: binding constants and mechanisms. ACS Nano 2011; 5: 3456-68.
128. [128] Sisavath N, Le Saux T, Leclercq L, Cottet H. Effect of dendrimer generation on the interactions between human serum albumin and dendrigraft polylysines. Langmuir 2014; 30: 4450-7.
129. [129] Liu N, Hao Y, Yin Z, Ma M, Wang L, Zhang X. Self-assembled human serum albumin-coated complexes for gene delivery with improved transfection. Die Pharmazie-Int J Pharm Sci 2012; 67: 174-81.
130. [130] Zhou J, Zhang X, Li M, et al. Novel lipid hybrid albumin nanoparticle greatly lowered toxicity of pirarubicin. Mol pharm 2013; 10: 3832-41.
131. [131] Huang HC, Barua S, Sharma G, Dey SK, Rege K. Inorganic nanoparticles for cancer imaging and therapy. J Control Release 2011; 155: 344-57.
132. [132] Mahon E, Salvati A, Baldelli BF, Lynch I, Dawson KA. Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery". J Control Release 2012; 161: 164-74.
133. [133] Chan PH, Chen YC. Human serum albumin stabilized gold nanoclusters as selective luminescent probes for staphylococcus aureus and methicillin-resistant staphylococcus aureus. Anal Chem 2012; 84: 8952-6.
134. [134] Cañaveras F, Madueño R, Sevilla JM, Blázquez M, Pineda T. Role of the functionalization of the gold nanoparticle surface on the formation of bioconjugates with human serum albumin. J Phys Chem C 2012; 116: 10430-7.
135. [135] Gebauer JS, Malissek M, Simon S, et al. Impact of the nanoparticle– protein corona on colloidal stability and protein structure. Langmuir 2012; 28: 9673-9.
136. [136] Ge C, Du J, Zhao L, et al. Binding of blood proteins to carbon nanotubes reduces cytotoxicity Proc Nat Acad Sci USA 2011; 108: 16968-73.
137. [137] Treuel L, Brandholt S, Maffre P, Wiegele S, Shang L, Nienhaus GU. Impact of protein modification on the protein corona on nanoparticles and nanoparticle-cell interactions. ACS Nano 2014; 8: 503-13.
138. [138] Mariam J, Sivakami S, Kothari D, Dongre P. Bioactivity of albumins bound to silver nanoparticles. Protein J 2014; 33: 258-66.
139. [139] De Paoli SH, Diduch LL, Tegegn, TZ, et al. The effect of protein corona composition on the interaction of carbon nanotubes with human blood platelets. Biomaterials 2014; 35: 6182-94.
140. [140] Dautova Y, Kozlova D, Skepper JN, Epple M, Bootman MD. Proudfoot D, Fetuin-A and albumin alter cytotoxic effects of calcium phosphate nanoparticles on human vascular smooth muscle cells. Plos One 2014; 9: e97565.
141. [141] Schäffler M, Sousa F, Wenk A, et al. Blood protein coating of gold nanoparticles as potential tool for organ targeting. Biomaterials 2014; 35: 3455-66.
142. [142] Lu N, Li J, Tian R, Peng YY. Binding of human serum albumin to single-walled carbon nanotubes activated neutrophils to increase production of hypochlorous acid, the oxidant capable of degrading nanotubes. Chem Res Toxicol 2014; 27: 1070-7.
143. [143] Quan Q, Xie J, Gao H, et al. HSA coated iron oxide nanoparticles as drug delivery vehicles for cancer therapy. Mol Pharm 2011; 8: 1669-76.
144. [144] Barenholz Y. Doxil®-The first FDA-approved nano-drug: lessons learned. J Control Release 2012; 160: 117-34.
145. [145] Nigam P, Waghmode S, Louis M, Wangnoo S, Chavan P, Sarkar D. Graphene quantum dots conjugated albumin nanoparticles for targeted drug delivery and imaging of pancreatic cancer. J Mater Chem B 2014; 2: 3190-5.
146. [146] Topete A, Alatorre-Meda M, Iglesias P, et al. Fluorescent drugloaded, polymeric-based, branched gold nanoshells for localized multimodal therapy and imaging of tumoral cells. ACS Nano 2014; 8: 2725-38.
147. [147] Xie J, Wang J, Niu, G, et al. Human serum albumin coated iron oxide nanoparticles for efficient cell labeling. Chem Commun 2010; 46: 433-5.
148. [148] Lee JY, Nam DH, Oh MH, Serum-stable quantum dot--protein hybrid nanocapsules for optical bio-imaging. Nanotechnology 2014; 25: 175702.
149. [149] Aviv H, Bartling S, Grinberg I, Margel S. Synthesis and characterization of Bi2O3/HSA core-shell nanoparticles for X-ray imaging applications. J Biomed Mater Res B 2013; 101B: 131-8.
150. [150] Zor E, Hatay Patir I, Bingol H, Ersoz M. An electrochemical biosensor based on human serum albumin/graphene oxide/3-aminopropyltriethoxysilane modified ITO electrode for the enantioselective discrimination of d-and l-tryptophan. Biosens Bioelectron 2013; 42: 321-5.
151. [151] Mortimer GM, Butcher NJ, Musumeci AW, Deng ZJ, Martin DJ, Minchin RF. Cryptic epitopes of albumin determine mononuclear phagocyte system clearance of nanomaterials. ACS Nano 2014; 8: 3357-66.
152. [152] Zhang S, Kucharski C, Doschak MR, Sebald W, Uluda H. Polyethylenimine-PEG coated albumin nanoparticles for BMP-2 delivery. Biomaterials 2010; 31: 952-63.
153. [153] Yuge S, Akiyama M, Komatsu T. An Escherichia coli trap in human serum albumin microtubes. Chem Commun 2014; 50: 9640-3.
154. [154] Yang M, Hoppmann S, Chen L, Cheng Z. Human serum albumin conjugated biomolecules for cancer molecular imaging. Curr Pharm Des 2012; 18: 1023-31.
155. [155] Xu Y, Luo J, Chen Z. Zn2+-responsive bimodal magnetic resonance imaging and fluorescence imaging agents and their interaction with human serum albumin. Eur J Inorg Chem 2014; 20: 3208-15.
156. [156] Alexander VM, Sano K, Yu Z, et al. Galactosyl human serum albumin-NMP1 conjugate: a near infrared (NIR)-activatable fluorescence imaging agent to detect peritoneal ovarian cancer metastases. Bioconjugate Chem 2012; 23: 1671-9.
157. [157] Chen Q, Liang C, Wang X, He J, Li Y, Liu Z. An albumin-based theranostic nano-agent for dual-modal imaging guided photothermal therapy to inhibit lymphatic metastasis of cancer post surgery. Biomaterials 2014; 35: 9355-62.
158. [158] Bu L, Ma X, Tu Y, Shen B, Cheng Z. Optical image-guided cancer therapy. Curr Pharm Des 2013; 14: 723-32.